MARKSANS PHARMA
Quarterly Results Analysis [Mar2025]
MARKSANS PHARMA Quarterly Results
Consolidated | Mar2025 UnAudited |
Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹708 Cr | ₹682 Cr | ₹642 Cr | ₹591 Cr | ₹560 Cr | ₹586 Cr | ₹531 Cr | ₹500 Cr |
Expenses | ₹583 Cr | ₹543 Cr | ₹506 Cr | ₹462 Cr | ₹450 Cr | ₹453 Cr | ₹417 Cr | ₹398 Cr |
Operating Income | ₹126 Cr | ₹139 Cr | ₹136 Cr | ₹128 Cr | ₹110 Cr | ₹133 Cr | ₹114 Cr | ₹102 Cr |
Other Income | ₹17 Cr | ₹28 Cr | ₹11 Cr | ₹15 Cr | ₹17 Cr | ₹5 Cr | ₹19 Cr | ₹10 Cr |
Interest | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹5 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr |
Depreciation | ₹23 Cr | ₹21 Cr | ₹20 Cr | ₹20 Cr | ₹21 Cr | ₹22 Cr | ₹18 Cr | ₹14 Cr |
Profit Before Tax | ₹116 Cr | ₹143 Cr | ₹125 Cr | ₹120 Cr | ₹100 Cr | ₹113 Cr | ₹114 Cr | ₹97 Cr |
Profit After Tax | ₹91 Cr | ₹105 Cr | ₹98 Cr | ₹89 Cr | ₹78 Cr | ₹83 Cr | ₹84 Cr | ₹70 Cr |
EPS | ₹2.00 | ₹2.31 | ₹2.13 | ₹1.96 | ₹1.73 | ₹1.84 | ₹1.84 | ₹1.52 |
Industry Peers & Returns | 1W | 1M | 1Y |
MARKSANS PHARMA | 0.9% | 1.2% | 35.7% |
SUN PHARMACEUTICAL INDUSTRIES | 3.6% | 2.5% | 6.2% |
DIVIS LABORATORIES | -2.9% | 1.5% | 48.1% |
CIPLA | -0.1% | -2.4% | -1.4% |
TORRENT PHARMACEUTICALS | 2.5% | 4.9% | 15.2% |
DR REDDYS LABORATORIES | -0.7% | -6.4% | -5.2% |
MANKIND PHARMA | 5% | 12% | 27.4% |
ZYDUS LIFESCIENCES | -1.1% | -0.7% | -16.8% |
LUPIN | 2% | -2.9% | 5.9% |
MARKSANS PHARMA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 3.90 % |
Y-o-Y | 26.51 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Mar2025 | ₹708 Cr | 3.90 | |
Dec2024 | ₹682 Cr | 6.22 | |
Sep2024 | ₹642 Cr | 8.69 | |
Jun2024 | ₹591 Cr | 5.47 | |
Mar2024 | ₹560 Cr | -4.46 | |
Dec2023 | ₹586 Cr | 10.33 | |
Sep2023 | ₹531 Cr | 6.24 | |
Jun2023 | ₹500 Cr | - |
MARKSANS PHARMA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -9.38 % |
Y-o-Y | 14.70 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Mar2025 | ₹126 Cr | -9.38 | |
Dec2024 | ₹139 Cr | 2.27 | |
Sep2024 | ₹136 Cr | 5.64 | |
Jun2024 | ₹128 Cr | 17.14 | |
Mar2024 | ₹110 Cr | -17.58 | |
Dec2023 | ₹133 Cr | 16.74 | |
Sep2023 | ₹114 Cr | 11.75 | |
Jun2023 | ₹102 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -12.78 % |
Y-o-Y | -9.35 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Mar2025 | 17.75% | -12.78 | |
Dec2024 | 20.35% | -3.74 | |
Sep2024 | 21.14% | -2.80 | |
Jun2024 | 21.75% | 11.08 | |
Mar2024 | 19.58% | -13.74 | |
Dec2023 | 22.7% | 5.83 | |
Sep2023 | 21.45% | 5.20 | |
Jun2023 | 20.39% | - |
MARKSANS PHARMA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -13.65 % |
Y-o-Y | 16.85 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Mar2025 | ₹91 Cr | -13.65 | |
Dec2024 | ₹105 Cr | 7.47 | |
Sep2024 | ₹98 Cr | 9.76 | |
Jun2024 | ₹89 Cr | 14.71 | |
Mar2024 | ₹78 Cr | -6.41 | |
Dec2023 | ₹83 Cr | -1.06 | |
Sep2023 | ₹84 Cr | 19.04 | |
Jun2023 | ₹70 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -16.87 % |
Y-o-Y | -7.58 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2025 | 12.81 % | -16.87 | |
Dec2024 | 15.41 % | 1.18 | |
Sep2024 | 15.23 % | 0.99 | |
Jun2024 | 15.08 % | 8.80 | |
Mar2024 | 13.86 % | -2.05 | |
Dec2023 | 14.15 % | -10.33 | |
Sep2023 | 15.78 % | 11.99 | |
Jun2023 | 14.09 % | - |
MARKSANS PHARMA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -13.42 % |
Y-o-Y | 15.61 % |
Quarters | EPS | % Change | |
---|---|---|---|
Mar2025 | ₹2 | -13.42 | |
Dec2024 | ₹2.31 | 8.45 | |
Sep2024 | ₹2.13 | 8.67 | |
Jun2024 | ₹1.96 | 13.29 | |
Mar2024 | ₹1.73 | -5.98 | |
Dec2023 | ₹1.84 | 0.00 | |
Sep2023 | ₹1.84 | 21.05 | |
Jun2023 | ₹1.52 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD